Multicentre service evaluation of injectable cabotegravir and rilpivirine delivery and outcomes across 12 UK clinics ( SHARE LAI ‐net)
HIV Medicine · 2024
DOI: 10.1111/hiv.13679 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift HIV Medicine, 2024. Verfasst von Kyle Ring und 31 weiteren Autor:innen. Beteiligte Einrichtung: Barts Health NHS Trust, London, UK. Hauptthemen laut MEDLINE: Rilpivirine, HIV Infections, Anti-HIV Agents, Pyridones. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Wellcome Trust.
Abstract (Originalsprache)
Introduction
Long‐acting injectable cabotegravir + rilpivirine (CAB + RPV LAI) was approved for use in virally suppressed adults in the England and Wales national health service in November 2021. We describe a service evaluation of delivery processes and outcomes in 12 clinics.
Methods
Centres populated a database using information from local policies and clinical records. Services were asked to describe approval processes, clinic pathways, and adherence to national guidelines. Additional data were collected on reasons for regimen choice, treatment discontinuations, and management of viraemia.
Results
In total, 518 adults from 12 clinics were approved for CAB + RPV LAI between February 2022 and December 2023. Of the 518 people approved for CAB + RPV LAI, 423 received at least one injection. Median duration on CAB + RPV was 7.5 months (interquartile range 3.7–11.3). In total, 97% of injections were administered within the ±7‐day window. Virological failure occurred in 0.7%, and 6% discontinued CAB + RPV.
Conclusion
In this large UK ‐based cohort, robust approval processes and clinic protocols facilitated on‐time injections and low rates of both discontinuation and virological failure.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Barts Health NHS Trust, London, UK.
- Queen Mary University of London, London, UK.
- Imperial College Healthcare NHS Trust, London, UK.
- Royal Free London NHS Foundation Trust, London, UK.
- Institute for Global Health, UCL, London, UK.
- Guy's and St Thomas' NHS Foundation Trust, London, UK.
ORCID-Profile: Kyle Ring, Tristan J Barber, Daniella Chilton, Gemma White, Fiona Clark, Laura Waters, Chloe Orkin
Förderung
- Wellcome Trust
Zitieren
APA
Ring, K., Smuk, M., Shongwe, M., Okonta, L., Mackie, N. E., Ayres, S., Barber, T. J., Akodu, J., Ferro, F., Chilton, D., Hurn, E., Halai, B., Barchi, W., Ali, A., Darko, S., White, G., Clarke, E., Clark, F., Ali, B., …, & Orkin, C. (2024). Multicentre service evaluation of injectable cabotegravir and rilpivirine delivery and outcomes across 12 UK clinics ( SHARE LAI ‐net). HIV Medicine. https://doi.org/10.1111/hiv.13679
Vancouver
Ring K, Smuk M, Shongwe M, Okonta L, Mackie NE, Ayres S, et al. Multicentre service evaluation of injectable cabotegravir and rilpivirine delivery and outcomes across 12 UK clinics ( SHARE LAI ‐net). HIV Medicine. 2024. doi:10.1111/hiv.13679
BibTeX
@article{Ring2024,
author = {Ring, Kyle and Smuk, Melanie and Shongwe, Moses and Okonta, Leroy and Mackie, Nicola E and Ayres, Sara and Barber, Tristan J and Akodu, Jane and Ferro, Filippo and Chilton, Daniella and Hurn, Eliot and Halai, Bhavna and Barchi, Will and Ali, Asim and Darko, Sandra and White, Gemma and Clarke, Emily and Clark, Fiona and Ali, Bazga and Arumainayagam, Joseph and Quinn, Gaynor and Boffito, Marta and Byrne, Ruth and Naous, Nadia and Leung, Suki and Umaipalan, Athavan and Thornton, Brian and Bayliss, David and McLoughlin, Catherine and Foster, Jonathan and Waters, Laura and Orkin, Chloe},
title = {Multicentre service evaluation of injectable cabotegravir and rilpivirine delivery and outcomes across 12 UK clinics ( SHARE LAI ‐net)},
journal = {HIV Medicine},
year = {2024},
doi = {10.1111/hiv.13679}
}
EUVIMED